RxDoctor Payments Data

Haleigh Kleinman, PA

Surgical · Washington, DCNPI 1851858484

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Kestra Medical Technology Services, Inc. at 28.8% of the total. 2025 is the largest year on record at $571, 3.5 times the $164 reported in 2023.

$1,287in general payments, 2019–2025

Across 12 payments — averaging $107.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kestra Medical Technology Services, Inc.$370
  • Inspire Medical Systems, Inc.$150
  • Bridgebio Pharma, Inc.$142
  • Abbott$137
  • GSK$125
  • Amgen$125
  • plus $238 from 5 others

What the payments were for

  • Food & beverage$1,287100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,287 in reported general payments places this provider in the 85th percentile of 67 surgical providers in District of Columbia.

See all surgical providers in District of Columbia

Medicare billing

Part B allowed, 2024
$34,679
Medicare patients
310
Services billed
443

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban45$55,707
JardianceEmpagliflozin27$34,775
EntrestoSacubitril/Valsartan18$18,261
Metoprolol Succinate65$920
Valsartan21$862
Losartan Potassium52$821
Rosuvastatin Calcium67$820
Ezetimibe18$523
Amlodipine Besylate54$364
Atorvastatin Calcium48$336
Carvedilol16$248
Doxazosin Mesylate12$220
Olmesartan Medoxomil13$219
Ammonium Lactate11$142
Lisinopril16$129

Paid to pharmacies, not to this prescriber.

Other surgical in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →